X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $11.65 | -100,000 | 617,470 | -14% | -$1,165,000 | |||||
| M | 2024-10-18 | VRNA | Verona Pharma Plc | Zaccardelli David | Pres, CEO | S - Sale | $4.38 | -514,152 | 14,736,552 | -3% | -$2,253,237 | |||||
| M | 2024-10-18 | VRNA | Verona Pharma Plc | Hahn Mark W | CFO | S - Sale | $4.38 | -525,768 | 13,813,920 | -4% | -$2,303,773 | |||||
| AD | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | Polaris Management Co. Vii, L.L.C. | 10% | P - Purchase | $11.00 | +909,090 | 909,090 | New | +$9,999,990 | |||||
| M | 2024-10-18 | TYRA | Tyra Biosciences, Inc. | Harris Todd | Pres, CEO | S - Sale | $27.28 | -62,720 | 1,355,927 | -4% | -$1,711,247 | |||||
| D | 2024-10-21 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $366.99 | -7,782 | 6,978 | -53% | -$2,855,916 | |||||
2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $30.00 | -716 | 343,311 | 0% | -$21,483 | ||||||
2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $30.00 | -847 | 1,015,188 | 0% | -$25,413 | ||||||
2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $30.00 | -924 | 1,002,892 | 0% | -$27,723 | ||||||
2024-10-18 | JANX | Janux Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $44.75 | +1,200,000 | 10,365,652 | +13% | +$53,700,000 | ||||||
| D | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $30.00 | -814 | 0 | -100% | -$24,422 | |||||
2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $30.00 | -1,570 | 188,245 | -1% | -$47,104 | ||||||
| D | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief Medical Officer | S - Sale+OE | $30.00 | -816 | 0 | -100% | -$24,482 | |||||
2024-10-18 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $11.19 | -2,526 | 204,857 | -1% | -$28,266 | ||||||
| M | 2024-10-18 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $35.16 | -13,535 | 5,868,468 | 0% | -$475,879 | |||||
| M | 2021-05-03 | ALDX | Aldeyra Therapeutics, Inc. | Miller-Rich Nancy | Dir | P - Purchase | $11.33 | +922 | 922 | New | +$10,447 | |||||
2024-10-18 | CTLT | Catalent, Inc. | Ferraro Joseph Anthony | SVP, GC, CCO | S - Sale | $59.97 | -320 | 23,967 | -1% | -$19,190 | ||||||
| DM | 2024-10-16 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale+OE | $31.41 | -91,634 | 605,417 | -13% | -$2,878,038 | |||||
| D | 2024-10-16 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale+OE | $13.67 | -208,836 | 0 | -100% | -$2,855,051 | |||||
2024-10-16 | WVE | Wave Life Sciences Ltd. | Bolno Paul | Pres, CEO | S - Sale | $15.00 | -90,474 | 268,585 | -25% | -$1,357,110 | ||||||
| D | 2024-10-17 | KRRO | Korro Bio, Inc. | Agarwal Vineet | CFO | S - Sale+OE | $78.26 | -10,216 | 0 | -100% | -$799,527 | |||||
| DM | 2024-10-16 | JANX | Janux Therapeutics, Inc. | Avalon Ventures Xi, L.P. | 10% | S - Sale+OE | $46.30 | -1,673,128 | 7,377,765 | -18% | -$77,472,371 | |||||
2024-10-16 | TRDA | Entrada Therapeutics, Inc. | Sethuraman Natarajan | Pres, Research, Develop. | S - Sale | $18.00 | -600 | 183,216 | 0% | -$10,800 | ||||||
2024-10-17 | ESPR | Esperion Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale | $2.12 | -107 | 162,552 | 0% | -$227 | ||||||
| M | 2024-10-16 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $35.29 | -36,684 | 5,882,003 | -1% | -$1,294,437 | |||||
| M | 2024-10-15 | TYRA | Tyra Biosciences, Inc. | Harris Todd | Pres, CEO | S - Sale | $25.77 | -58,726 | 1,418,647 | -4% | -$1,513,271 | |||||
| D | 2024-10-16 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $38.31 | -53 | 35,064 | 0% | -$2,031 | |||||
| D | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | Northpond Ventures II Gp, LLC | 10% | P - Purchase | $11.00 | +763,636 | 2,238,244 | +52% | +$8,399,996 | |||||
| M | 2024-10-15 | DRUG | Bright Minds Biosciences Inc. | Cormorant Asset Management, LP | 10% | P - Purchase | $7.65 | +422,591 | 875,000 | +93% | +$3,234,387 | |||||
| D | 2024-10-15 | ANNX | Annexon, Inc. | Yednock Ted | EVP, CHIEF INNOVATION OFFICER | S - Sale+OE | $7.41 | -5,408 | 71,365 | -7% | -$40,073 | |||||
2024-10-15 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $27.67 | -1,270 | 189,815 | -1% | -$35,143 | ||||||
| D | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | Ah Equity Partners Bio I, L.L.C. | 10% | P - Purchase | $11.00 | +727,272 | 2,125,339 | +52% | +$7,999,992 | |||||
| D | 2024-10-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $102.28 | -27,000 | 188,113 | -13% | -$2,761,631 | |||||
| D | 2024-10-15 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $26.87 | -17,000 | 109,975 | -13% | -$456,790 | |||||
| D | 2024-10-16 | SPRY | Ars Pharmaceuticals, Inc. | Scott Kathleen D. | CFO | S - Sale+OE | $16.00 | -12,500 | 13,199 | -49% | -$200,000 | |||||
2024-10-15 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $14.88 | -100,000 | 11,765,600 | -1% | -$1,487,595 | ||||||
2024-10-15 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $14.88 | -100,000 | 11,765,600 | -1% | -$1,487,595 | ||||||
2024-10-15 | RANI | Rani Therapeutics Holdings, Inc. | South Cone Investments Limited Partnership | 10% | S - Sale | $2.65 | -3,829,360 | 8,302,194 | -32% | -$10,141,674 | ||||||
| D | 2024-10-16 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale+OE | $48.52 | -25,000 | 94,018 | -21% | -$1,213,010 | |||||
| D | 2024-10-15 | UPB | Upstream Bio, Inc. | Chimovits Erez | Dir, 10% | P - Purchase | $17.00 | +825,000 | 4,554,873 | +22% | +$14,025,000 | |||||
| D | 2024-10-15 | UPB | Upstream Bio, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $17.00 | +825,000 | 4,554,873 | +22% | +$14,025,000 | |||||
| D | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | Enavate Sciences Gp, LLC | 10% | P - Purchase | $11.00 | +1,363,636 | 3,785,802 | +56% | +$14,999,996 | |||||
| D | 2024-10-15 | UPB | Upstream Bio, Inc. | Ai Upstream LLC | 10% | P - Purchase | $17.00 | +1,175,000 | 5,494,410 | +27% | +$19,975,000 | |||||
2024-10-17 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $2.64 | +1,300 | 132,832 | +1% | +$3,432 | ||||||
2024-10-15 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | P - Purchase | $1.50 | +15,636 | 0 | -100% | +$23,454 | ||||||
2024-10-16 | ADTX | Aditxt, Inc. | Hrt Financial LP | 10% | S - Sale | $1.17 | -25,534 | 0 | -100% | -$29,875 | ||||||
2024-10-16 | APRE | Aprea Therapeutics, Inc. | Duey Marc | Dir | P - Purchase | $4.39 | +30,000 | 240,715 | +14% | +$131,700 | ||||||
2024-10-15 | NATR | Natures Sunshine Products Inc | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $13.02 | -2,300 | 2,918,774 | 0% | -$29,946 | ||||||
2024-10-15 | ARCT | Arcturus Therapeutics Holdings Inc. | Chivukula Pad | Chief Scientific Officer, COO | S - Sale | $20.76 | -12,000 | 435,334 | -3% | -$249,121 | ||||||
| D | 2024-10-14 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale+OE | $30.15 | -40,000 | 286,286 | -12% | -$1,206,080 | |||||
| DM | 2024-10-15 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $30.37 | -20,961 | 74,158 | -22% | -$636,490 | |||||
| D | 2024-10-15 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $54.19 | -7,300 | 116,920 | -6% | -$395,554 | |||||
2024-10-15 | SDGR | Schrodinger, Inc. | Dugan Margaret | Chief Medical Officer | S - Sale | $17.78 | -1,531 | 13,469 | -10% | -$27,226 | ||||||
2024-10-11 | ZVRA | Zevra Therapeutics, Inc. | Watton Corey Michael | Dir | P - Purchase | $7.92 | +500 | 1,500 | +50% | +$3,958 | ||||||
| D | 2024-10-15 | LBPH | Longboard Pharmaceuticals, Inc. | Kaye Randall | CMO | S - Sale+OE | $59.04 | -16,667 | 17,920 | -48% | -$983,936 | |||||
2024-10-16 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $2.70 | +10,000 | 131,532 | +8% | +$27,000 | ||||||
2024-10-15 | APRE | Aprea Therapeutics, Inc. | Gilad Oren | Pres, CEO | P - Purchase | $2.90 | +250 | 334,695 | 0% | +$725 | ||||||
2024-10-14 | APRE | Aprea Therapeutics, Inc. | Duey Marc | Dir | P - Purchase | $2.58 | +190 | 210,715 | 0% | +$490 | ||||||
2024-10-11 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | SrVP, CFO, Prin Fin, Acct Ofcr | P - Purchase | $2.46 | +50 | 19,368 | 0% | +$123 | ||||||
2024-10-14 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale | $11.11 | -2,576 | 500,548 | -1% | -$28,613 | ||||||
2024-10-14 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $11.11 | -2,260 | 207,383 | -1% | -$25,103 | ||||||
2024-10-14 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale | $11.11 | -1,527 | 152,798 | -1% | -$16,961 | ||||||
2024-10-14 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale | $11.11 | -3,892 | 311,076 | -1% | -$43,231 | ||||||
2024-10-14 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $11.11 | -8,053 | 2,400,455 | 0% | -$89,450 | ||||||
| D | 2024-10-14 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $11.11 | -1,146 | 118,574 | -1% | -$12,729 | |||||
| D | 2024-10-14 | CDMO | Avid Bioservices, Inc. | Kwietniak Matthew R. | Chief Commercial Officer | S - Sale+OE | $10.15 | -119 | 25,407 | 0% | -$1,208 | |||||
2024-10-14 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.14 | +100,000 | 1,200,000 | +9% | +$14,000 | ||||||
| D | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | Polaris Management Co. Vii, L.L.C. | 10% | P - Purchase | $11.00 | +909,090 | 909,090 | New | +$9,999,990 | |||||
2024-10-14 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $57.19 | -250 | 56,488 | 0% | -$14,298 | ||||||
| D | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | 5Am Partners Vi, LLC | 10% | P - Purchase | $11.00 | +909,090 | 2,927,915 | +45% | +$9,999,990 | |||||
| D | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | Nashat Amir | Dir, 10% | P - Purchase | $11.00 | +909,090 | 909,090 | New | +$9,999,990 | |||||
| D | 2024-10-15 | CAMP | Camp4 Therapeutics Corp | Schwab Andrew J. | Dir, 10% | P - Purchase | $11.00 | +909,090 | 2,625,145 | +53% | +$9,999,990 | |||||
2024-01-30 | AXIM | Axim Biotechnologies, Inc. | Valencia Catalina | Pres, Dir, 10% | P - Purchase | $0.00 | +1,086,216 | 28,608,220 | +4% | +$0 | ||||||
2024-10-11 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $6.01 | -7,500 | 1,235,472 | -1% | -$45,075 | ||||||
| D | 2024-10-14 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $355.88 | -7,792 | 6,426 | -55% | -$2,773,017 | |||||
2024-10-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $13.57 | -10,757 | 236,854 | -4% | -$146,004 | ||||||
2024-10-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $13.52 | -15,271 | 895,941 | -2% | -$206,433 | ||||||
| D | 2024-10-14 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $25.00 | -3,290 | 24,592 | -12% | -$82,250 | |||||
| M | 2024-10-01 | NATR | Natures Sunshine Products Inc | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $13.33 | -10,895 | 2,921,074 | 0% | -$145,189 | |||||
2024-10-11 | APRE | Aprea Therapeutics, Inc. | Seizinger Bernd R. | Dir | P - Purchase | $2.68 | +10,000 | 44,730 | +29% | +$26,800 | ||||||
| M | 2024-10-10 | APRE | Aprea Therapeutics, Inc. | Gilad Oren | Pres, CEO | P - Purchase | $2.58 | +1,150 | 334,445 | 0% | +$2,971 | |||||
2024-10-10 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | SrVP, CFO, Prin Fin, Acct Ofcr | P - Purchase | $2.61 | +450 | 19,318 | +2% | +$1,175 | ||||||
| D | 2024-10-10 | CDMO | Avid Bioservices, Inc. | Richieri Richard A. | Chief Operations Officer | S - Sale+OE | $10.05 | -2,232 | 44,922 | -5% | -$22,432 | |||||
| D | 2024-10-10 | CDMO | Avid Bioservices, Inc. | Kwietniak Matthew R. | Chief Commercial Officer | S - Sale+OE | $10.05 | -982 | 25,191 | -4% | -$9,869 | |||||
| D | 2024-10-10 | CDMO | Avid Bioservices, Inc. | Green Nicholas Stewart | Pres, CEO | S - Sale+OE | $10.05 | -17,173 | 226,653 | -7% | -$172,589 | |||||
2024-10-10 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $52.76 | -7,465 | 92,301 | -7% | -$393,853 | ||||||
2024-10-09 | BFRG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | S - Sale | $2.59 | -5,695 | 2,442,446 | 0% | -$14,727 | ||||||
| D | 2024-10-09 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $38.24 | -15,625 | 307,972 | -5% | -$597,568 | |||||
| A | 2023-06-06 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | P - Purchase | $0.50 | +5,000,000 | 14,000,000 | +56% | +$2,500,000 | |||||
| M | 2024-09-25 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | S - Sale | $1.16 | -92,190 | 13,683,845 | -1% | -$106,815 | |||||
| M | 2024-10-08 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $28.11 | -51,145 | 1,016,035 | -5% | -$1,437,585 | |||||
| M | 2024-10-08 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $28.07 | -29,977 | 1,003,816 | -3% | -$841,334 | |||||
| D | 2024-10-08 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $28.17 | -10,420 | 22,341 | -32% | -$293,557 | |||||
2024-10-10 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.16 | +76,371 | 121,516,682 | 0% | +$12,072 | ||||||
2024-10-08 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $232.22 | -16,175 | 47,739,596 | 0% | -$3,756,092 | ||||||
| AM | 2024-07-02 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | S - Sale | $8.62 | -223,965 | 13,776,035 | -2% | -$1,930,797 | |||||
2024-10-09 | ENTO | Entero Therapeutics, Inc. | Romano Sarah | CFO | S - Sale | $0.45 | -476 | 18,014 | -3% | -$212 | ||||||
2024-10-08 | NUVB | Nuvation Bio Inc. | Mashal Robert | Dir | P - Purchase | $2.20 | +100,000 | 100,000 | New | +$220,000 | ||||||
2024-10-08 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $13.83 | -100,000 | 11,865,600 | -1% | -$1,382,775 | ||||||
2024-10-08 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $13.83 | -100,000 | 11,865,600 | -1% | -$1,382,775 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |